Sharemaestro Newsreel

Korro Bio director Jean Francois Formela sells $29,916 in shares

Korro Bio director Jean Francois Formela sold 2,143 shares of the company's common stock for approximately $29,916 on August 11, 2026, under a Rule 10b5-1 trading plan. Despite recent volatility and a 67% year-to-date return, InvestingPro analysis suggests the stock may be overvalued. The …

Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan

Korro Bio director Jean Francois Formela's affiliated funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 2,143 shares of Korro Bio common stock on August 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan …

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway

Instil Bio (Nasdaq: TIL) reported a significantly trimmed net loss of $4.3 million in Q2 2026, down from $21.4 million in Q2 2025, driven by reduced operating expenses. The company also announced a strong cash position of $69.9 million, which is expected to fund …

Instil Bio, Inc. 2026: Revenue ($4.35M), Net income ($4.3M), EPS ($0.63) — 10-Q Summary

Instil Bio, Inc. reported its 2026 quarterly results, showing a significantly narrower net loss and reduced comprehensive loss compared to the previous year. This improvement is attributed to the company winding down development of its lead candidate, AXN-2510, and substantially cutting R&D activity and …

Form 8K Instil Bio Inc For: 13 August By Investing.com

This article reports on the filing of Form 8K by Instil Bio Inc. on August 13th, as tracked by Investing.com. The content itself is very brief, serving primarily as an announcement of the filing rather than providing detailed information about the filing's contents. It …

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio, Inc. (Nasdaq: TIL) reported its second quarter 2026 financial results, highlighting a cash position of approximately $69.9 million as of June 30, 2026, which is expected to fund operations beyond 2027. The biotechnology company is also actively evaluating potential acquisitions, in-licensing, and …

Instil Bio (TIL) slashes R&D spend and leans on Tarzana lease income in Q2 2026

Instil Bio (TIL) significantly reduced operating expenses and narrowed its net loss in Q2 2026 due to the discontinuation of certain R&D programs and restructuring efforts. The company reported a net loss of $4.3 million for the quarter and $8.5 million for the first …

CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates

CAMP4 Therapeutics reported a Q2 net loss of $33.5 million, significantly wider than the previous year, primarily due to a $20.9 million non-cash derivative loss, causing EPS of $(0.58) to miss estimates. Despite missing revenue consensus, the company's revenue rose 18.8% year-over-year. Post-quarter, CAMP4 …

Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …

Capricor: Q2 Earnings Snapshot

This article provides a brief "Q2 Earnings Snapshot" for Capricor. The full content of the article is not available beyond the title, indicating it may be a placeholder or an article with minimal information.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Hagens Berman is encouraging investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to come forward regarding a securities fraud class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements about the clinical trial data and regulatory pathway for …

Earnings call transcript: Capricor Therapeutics Q2 2026 loss narrows focus to FDA path

Capricor Therapeutics reported a wider-than-expected Q2 2026 loss of $0.70 per share but saw its stock surge 83.6% after hours due to positive investor focus on its updated regulatory strategy for deramiocel, its Duchenne muscular dystrophy treatment. The company announced the FDA is open …

Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ligand Pharmaceuticals (LGND) is back in focus after its recent second quarter report and reaffirmed 2026 guidance. The company posted US$63.69 million in quarterly revenue and US$48.51 …

MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal

Fortress Biotech: Q2 Earnings Snapshot

Instil Bio expects $69.9M cash to fund plan beyond 2027

Top Generate Biomedicines (GENB) Competitors 2026

Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike

Damora Therapeutics director Andrew Cheng was granted 30,350 stock options on August 12, 2026, with an exercise price of $31.00 per share and an expiration date of August 12, 2036. These options will vest in equal monthly installments through August 12, 2029, contingent on …

Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng

Damora Therapeutics (DMRA) has filed a Form 3, an initial statement of beneficial ownership, for Andrew Cheng, identifying him as a new director. This filing officially establishes Cheng as a reporting person with the SEC, though it reports no stock transactions at this time. …

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," …

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Regeneron Pharmaceuticals Inc. (REGN) saw its stock price rally by 1.00% to $805.97, outperforming its competitors and the broader market on a strong trading day. This marked the stock's second consecutive day of gains, with the S&P 500 Index and Dow Jones Industrial Average …

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates

MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner

MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …

RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K

An investor in Rhythm Pharmaceuticals (NASDAQ: RYTM) has filed a notice to sell 5,079 shares of common stock, valued at $597,290.40. The sale is planned through Morgan Stanley Smith Barney LLC on or after August 13, 2026, on NASDAQ. These shares originate from stock …

Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake

Affinity Asset Advisors, LLC and Michael Cho have reported an 8.4% beneficial stake in Lexeo Therapeutics (LXEO) through an amended Schedule 13G filing. This includes 6,674,913 shares of common stock, with 867,302 shares issuable upon warrant exercise, as of June 30, 2026. The reporting …

Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance

Ardelyx (ARDX) experienced a 19.1% stock drop following a US$36 million shelf registration for an ESOP and its Q2 earnings report. Despite a net loss, the company raised its 2026 IBSRELA revenue guidance to US$350–370 million, while reiterating XPHOZAH revenue expectations. This move signals …

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations

Aktis Oncology (NASDAQ:AKTS) recently reported its earnings, meeting the consensus estimate for EPS at ($0.44) and surpassing revenue expectations with $3.38 million. Despite the positive earnings surprise, the stock traded down 0.9% to $23.79, giving the company a market capitalization of approximately $1.27 billion. …

RYTM (RYTM) insider plans Form 144 sale of option and RSU shares

An insider at Rhythm Pharmaceuticals (RYTM) has filed a Form 144 indicating a proposed sale of 75,834 common shares through Morgan Stanley Smith Barney LLC. This total includes 56,601 shares from stock option exercises dated August 13, 2026, and 19,233 shares from Restricted Stock …

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss

Elicio Therapeutics reported a net loss of $20.0 million for the first half of 2026 and faces substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company's lead Phase 2 …

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Elicio Therapeutics: Q2 Earnings Snapshot

Alumis Inc. (ALMS) reports $235M loss but ends quarter with $502M cash

Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue